4basebio (LON:4BB) Stock Price Up 2% - Here's Why

4basebio PLC (LON:4BB - Get Free Report) rose 2% during trading on Tuesday . The stock traded as high as GBX 1,150 ($15.60) and last traded at GBX 1,147 ($15.56). Approximately 146 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 978 shares. The stock had previously closed at GBX 1,125 ($15.26).

Analyst Ratings Changes

Separately, Royal Bank of Canada restated an "outperform" rating and issued a GBX 1,600 ($21.71) price objective on shares of 4basebio in a report on Thursday, March 13th.

4basebio Trading Down 2.2%

The company has a market cap of £140.97 million, a price-to-earnings ratio of -1,410.90 and a beta of 1.09. The company's 50 day moving average price is GBX 1,133.51 and its 200 day moving average price is GBX 1,174.91. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73.

Insider Buying and Selling at 4basebio

In other news, insider Heikki Lanckriet acquired 2,400 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was acquired at an average cost of GBX 1,205 ($16.35) per share, with a total value of £28,920 ($39,240.16). Also, insider Amy Walker bought 1,151 shares of the stock in a transaction that occurred on Friday, February 28th. The stock was purchased at an average price of GBX 1,120 ($15.20) per share, for a total transaction of £12,891.20 ($17,491.45). Corporate insiders own 68.44% of the company's stock.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.